AVI-105
/ ABVision
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 21, 2020
BioSuperior anti-CD47 therapeutic antibody (AVI-105)
(BioSpace)
- "AbVision, Inc…announced today that the Company has developed a biosuperior anti-CD47 therapeutic antibody (AVI-105)…showed comparable binding affinity to its targets, comparable neutralizing activity in receptor-ligand blockade studies, and comparable anti-tumor activity in animal studies…AVI-105 demonstrated more potent macrophage-mediated phagocytosis than its reference antibody …AVI-105 induced less hemagglutination, indicating the biosuperior anti-CD47 antibody may generate minimized level of toxicity in vivo in comparison to the toxicity level from its reference antibody."
Preclinical • Oncology
1 to 1
Of
1
Go to page
1